B-MS' Ixempra increases PFS in triple negative BC

US drug major Bristol-Myers Squibb says new study data show that Ixempra (ixabepilone) plus capecitabine resulted in a significant increase in progression-free survival in triple negative breast cancer compared to capectabine alone.

The study results, which are from a pooled analysis of approximately 2,000 patients enrolled in two Phase III clinical trials of Ixempra (046 and 048), were presented at the 2008 San Antonio Breast Cancer Symposium.

In the pooled analysis of the sub-set of 443 patients with triple negative breast cancer, data show that Ixempra plus capecitabine (191 patients) is the first combination regimen to demonstrate statistically-significant (p<0.0001) PFS compared to capecitabine (208 patients) alone.